Raymond James Financial Services Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,727	Closed	-$200K	–	3331
2022 Q3	$200K	Buy	+3,727	New	+$219K	﹤0.01%	2856
2019 Q3	–	Sell	-4,171	Closed	-$297K	–	2884
2019 Q2	$297K	Buy	4,171 +819	+24%	+$60.3K	﹤0.01%	2282
2019 Q1	$263K	Buy	+3,352	New	+$254K	﹤0.01%	2338
2018 Q4	–	Sell	-2,074	Closed	-$355K	–	2705
2018 Q3	$355K	Sell	2,074 -718	-26%	-$108K	﹤0.01%	2162
2018 Q2	$361K	Buy	2,792 +573	+26%	+$63.9K	﹤0.01%	2113
2018 Q1	$229K	Buy	+2,219	New	+$219K	﹤0.01%	2179
2016 Q3	–	Sell	-2,764	Closed	-$206K	–	2354
2016 Q2	$206K	Buy	+2,764	New	+$205K	﹤0.01%	1962
2015 Q4	–	Sell	-17,766	Closed	-$949K	–	1612
2015 Q3	$949K	Buy	+17,766	New	+$1.08M	0.02%	791

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's LGND Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 3,727 shares — an estimated $200K sold.

Raymond James Financial Services Advisors first reported a position in LGND in Q3 2015 and held it in 8 quarters. The position peaked at $949K in Q3 2015. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Raymond James Financial Services Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 3,727 Ligand Pharmaceuticals shares in Q4 2022, an estimated $200K.
Raymond James Financial Services Advisors first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Raymond James Financial Services Advisors's Ligand Pharmaceuticals position peaked at $949K in Q3 2015.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.